Predicting brain cancer outcome
Feb. 15, 2022—Red blood cell distribution width has prognostic value for many diseases, but it was not associated with overall survival in patients with glioblastoma, Vanderbilt researchers found.
Drug modifies epigenome in aggressive brain tumors: study
Jan. 5, 2022—A folic acid-like drug changed a DNA process within brain tumors of glioblastoma patients, according to results from a phase 1 clinical trial.
MRI view of brain tumor prognosis
Feb. 22, 2021—In patients with glioblastoma brain tumors, features detected on MRIs at diagnosis were associated with survival, Vanderbilt Medical Center investigators found.
Drug combos for glioblastoma
May. 3, 2016—Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
New approach may halt glioblastoma’s ability to grow
Jan. 16, 2014—Vanderbilt University researchers have discovered a “backdoor” approach to blocking an enzyme that fuels the growth of glioblastoma, the most common and most fatal form of brain cancer.
New drugs a good BET for brain cancer
Mar. 20, 2013—A novel class of drugs that target “BET” proteins may have broad utility for treating genetically diverse brain tumors.
Brain tumor TIP reveals new target
Feb. 4, 2013—The protein TIP-1 appears to be a novel prognostic marker for glioblastoma and may be a good therapeutic target for disrupting tumor-driven blood vessel development.
Network approach yields glioblastoma clues
Aug. 9, 2012—MicroRNA “regulatory networks” generated at Vanderbilt aid search for biomarkers and new drugs to treat glioblastoma, the most common and lethal primary brain tumor.